Trials / Withdrawn
WithdrawnNCT01269320
Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome. Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions. Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Femarelle | Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days |
Timeline
- Start date
- 2012-01-01
- First posted
- 2011-01-04
- Last updated
- 2012-08-28
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01269320. Inclusion in this directory is not an endorsement.